Please login to the form below

Not currently logged in
Email:
Password:

renal disorders

This page shows the latest renal disorders news and features for those working in and with pharma, biotech and healthcare.

Merck & Co signs deal with Amathus for neurodegenerative diseases

Merck & Co signs deal with Amathus for neurodegenerative diseases

In addition, Merck &Co will also retain the option to acquire Amathus and its pipeline containing mitochondrial targeted candidates for the treatment of neurodegenerative disorders and renal diseases.

Latest news

More from news
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...